Takashi Owa

Senior Corporate Group Officer

Eisai Co., Ltd.

Short Biography

Dr. Takashi Owa currently serves as the Senior Corporate Group Officer for External Innovation at Eisai Co., Ltd. He received his Ph.D. in 1991 from the University of Tokyo in Organic Chemistry and Chemical Biology, and joined Eisai Co., Ltd as a research scientist in the same year. In addition, he studied as a two-year, post-doctoral visiting scientist at Professor Stuart Schreiber’s Laboratory in the Department of Chemistry and Chemical Biology of Harvard University from 1996 to 1998. He has been responsible for leading the full product creation cycle from discovery research to clinical development for regulatory approval of innovative oncology products, including anticancer sulfonamides E7070/indisulam and E7820, the splicing factor SF3B modulator E7107 as well as two approved drugs Halaven/eribulin as a microtubule dynamics inhibitor and Lenvima/lenvatinib as a VEGFR/FGFR/PDGFR-alpha/RET/KIT tyrosine kinase inhibitor. After 14-year global R&D management in the US as the Chief Scientific Officer focusing on oncology, he returned to Japan in 2024, taking the present role and responsibility for the company. He also works for RIKEN as a special advisor to go over the drug discovery and medical technology platforms.

Presentation Topic: Discovery and clinical development of molecular glue degrader of the splicing factor RBM39

• Discovery research into E7070 (indisulam) and E7820 as the molecular glue degrader of the splicing factor RBM39

• Summary of the clinical development of E7070 and E7820

• Chemical biology study on RBM39